DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.

Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical models Anti-IL1RAP ADC targets ...

Growing Pipeline of ADC Candidates for Various Cancer Indications is Driving the IndustryDublin, April 25, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market - Global Industry Size, Share, ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today shared new preclinical data for ...

Researchers from Heidelberg Pharma AG have presented a new antibody-drug conjugate (ADC) that shows promise for treating pancreatic ductal adenocarcinoma (PDAC). The ADC, called hRS7 ATAC, targets ...

Third, Enhertu’s cysteine-based conjugation process is able to achieve a high drug-to-antibody ratio of around 7 to 8. This is much higher than the DAR’s of older generations of ADCs ...

The poster is available on Innate Pharma’s website. IPH4502 is a differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4, a cell adhesion ...

Additionally, in the framework of a licensing agreement and a collaborative endeavor to support innovative research, Debiopharm and Oncodesign Services will present promising new data illustrating how ...

PF-08052666 was designed to address the limitations of earlier anti-MSLN ADCs through a novel antibody, differentiated linker ...

Lotte Biologics, the biotech arm of Lotte Group, said on Thursday it has signed a deal with an Asia-based biotech company for ...